Palmitoylethanolamide as a Supplement: The Importance of Dose-Dependent Effects for Improving Nervous Tissue Health in an In Vitro Model DOI Open Access

Rebecca Galla,

Simone Mulè,

Sara Ferrari

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(16), С. 9079 - 9079

Опубликована: Авг. 21, 2024

Palmitoylethanolamide (PEA) is a highly lipophilic molecule with low solubility, making absorption difficult. Recent techniques like micronisation, ultra-micronisation and combining PEA solvents have improved their bioavailability stability. Our study analysed particle size differences kinetics using specific (PEAΩ DynoΩ) over time (0.5 h–6 h) in dose-dependent manner (200 mg–1800 mg). The results showed that PEAΩ DynoΩ achieved 82–63% at 3 h, compared to 30–60% for micronised, ultra-micronised commercial product, highlighting the optimal dose range of 300 mg–600 mg. In addition, 3D model peripheral nerve was utilised explain efficacy after gut passage support most effective (300 mg or 600 mg) level. DynoΩ, which are associated better intestinal PEA-micronised, allowed not only reduction inflammatory context but also an improvement well-being by increasing markers MPZ (26–36% vs. 8–15%), p75 (25–32% 13–16%) NRG1 (22–29.5% 11–14%). These highlight potential advanced formulations overcome solubility challenges maintain vitro efficacy, modulating well-being.

Язык: Английский

Palmitoylethanolamide as a Supplement: The Importance of Dose-Dependent Effects for Improving Nervous Tissue Health in an In Vitro Model DOI Open Access

Rebecca Galla,

Simone Mulè,

Sara Ferrari

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(16), С. 9079 - 9079

Опубликована: Авг. 21, 2024

Palmitoylethanolamide (PEA) is a highly lipophilic molecule with low solubility, making absorption difficult. Recent techniques like micronisation, ultra-micronisation and combining PEA solvents have improved their bioavailability stability. Our study analysed particle size differences kinetics using specific (PEAΩ DynoΩ) over time (0.5 h–6 h) in dose-dependent manner (200 mg–1800 mg). The results showed that PEAΩ DynoΩ achieved 82–63% at 3 h, compared to 30–60% for micronised, ultra-micronised commercial product, highlighting the optimal dose range of 300 mg–600 mg. In addition, 3D model peripheral nerve was utilised explain efficacy after gut passage support most effective (300 mg or 600 mg) level. DynoΩ, which are associated better intestinal PEA-micronised, allowed not only reduction inflammatory context but also an improvement well-being by increasing markers MPZ (26–36% vs. 8–15%), p75 (25–32% 13–16%) NRG1 (22–29.5% 11–14%). These highlight potential advanced formulations overcome solubility challenges maintain vitro efficacy, modulating well-being.

Язык: Английский

Процитировано

0